Loomis, Sayles & Company
ACOR

Loomis, Sayles & Company’s Acorda Therapeutics ACOR Stock Holding History

Loomis, Sayles & Company’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-4,340
Closed -$10.9M – 1015
2017
Q1 		$10.9M Buy
4,340
+4,338
+216,900% +$12.5M 0.03% 405
2016
Q4 		$4K Hold
2
– – ﹤0.01% 938
2016
Q3 		$5K Hold
2
– – ﹤0.01% 887
2016
Q2 		$6K Sell
2
-5
-71% -$16.3K ﹤0.01% 832
2016
Q1 		$24K Sell
7
-4,864
-100% -$20.2M ﹤0.01% 710
2015
Q4 		$25M Buy
4,871
+227
+5% +$992K 0.07% 216
2015
Q3 		$14.8M Buy
4,644
+19
+0.4% +$73.7K 0.04% 361
2015
Q2 		$18.5M Buy
4,625
+677
+17% +$2.62M 0.05% 348
2015
Q1 		$15.8M Sell
3,948
-112
-3% -$513K 0.04% 398
2014
Q4 		$19.9M Buy
4,060
+1,070
+36% +$4.59M 0.06% 334
2014
Q3 		$12.2M Buy
+2,990
New +$11.2M 0.04% 462

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Loomis, Sayles & Company's ACOR Position: Q2 2017 in Review

Loomis, Sayles & Company sold out of Acorda Therapeutics (ACOR) in Q2 2017, closing a stake of 4,340 shares — an estimated $10.9M sold.

Loomis, Sayles & Company first reported a position in ACOR in Q3 2014 and held it in 11 quarters. The position peaked at $25M in Q4 2015. 151 funds tracked by Wall St. Rank hold ACOR as of Q2 2017.

  • Loomis, Sayles & Company reported no remaining Acorda Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Loomis, Sayles & Company sold 4,340 Acorda Therapeutics shares in Q2 2017, an estimated $10.9M.
  • Loomis, Sayles & Company first reported a position in Acorda Therapeutics in Q3 2014 and held it in 11 quarters.
  • Loomis, Sayles & Company's Acorda Therapeutics position peaked at $25M in Q4 2015.
  • 151 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2017.

Based on Loomis, Sayles & Company's 13F filing for Q2 2017, filed 14 Aug 2017.